Besides nuclear retinoid receptors and cellular retinoid binding proteins also retinoic acid (RA)-synthesizing enzymes (using all-trans-retinal as substrate) and RA-catabolizing enzymes (producing hydroxylated products) may explain the specific effects of retinoids. In the past we have established an active role for 4-hydroxy-RA and 4-oxo-RA, which originally were considered to be inactive retinoids, but in fact are highly active modulators of positional specification in Xenopus development. Here we present evidence for a specific role of hydroxylated RA metabolites in the onset of neuronal differentiation. 4-Hydroxy-and 18-hydroxy-RA are products of the hydroxylation of RA by a novel cytochrome P450 (CYP)-type of enzyme, CYP26, expression of which is rapidly induced by RA. P19 embryonal carcinoma (EC) cell lines stably expressing hCYP26 undergo extensive and rapid neuronal differentiation in monolayer at already low concentrations of RA, while normally P19 cells under these conditions differentiate only in endoderm-like cells. Our results indicate that the effects on growth inhibition and RAR␤ transactivation of P19 EC cells are mediated directly by RA, while the onset of neuronal differentiation and the subsequent expression of neuronal markers is mediated by hCYP26 via the conversion of RA to its hydroxylated products.
INTRODUCTION
Vitamin A and its analogues, the retinoids (including the active metabolite retinoic acid (RA)), 2 have been shown to be important regulators of cellular growth, differentiation, and morphogenesis (De Luca et al., 1994; Gudas et al., 1994) . Moreover these molecules are believed to act as crucial signal molecules during vertebrate embryonic development (Gudas, 1994) , like the development of the limb, the central nervous system (CNS), the heart, the vertebrae, and neural crest derivatives. This is supported by the fact that retinoid deficiency during pregnancy often results in congenital abnormalities of the embryo, while exposure to retinoids at elevated levels is teratogenic. The effects of RA are mediated at different levels, but most importantly through gene transcription, via interactions with multiple nuclear receptors (RARs and RXRs) which are members of the steroid/thyroid/vitamin D superfamily of nuclear receptors and use RA and 9-cis-RA as high-affinity ligands (Mangelsdorf et al., 1994) . RAR-RXR heterodimers bind to RA response elements (RAREs) in the promoter regions of target genes and regulate transcription in a liganddependent manner (Zhang et al., 1995; Chambon, 1996) . Additionally, multiple enzymatic pathways to synthesize as well as metabolize RA exist and may contribute to the profound effects of retinoids (Napoli et al., 1995) . 4-Hydroxy-RA and 4-oxo-RA, two metabolites of RA, are formed by a CYP-mediated reaction involving RAhydroxylase (CYP26) (Ray et al., 1997; White et al., 1997; .
Until recently, 4-hydroxylation of RA was considered to be an inactivation pathway during growth and differentiation (Williams et al., 1987) . However, in contrast, 4-oxo-RA was found to be a highly active metabolite which can modulate positional specification in early amphibian embryos (Pijnappel et al., 1993) and is a potent inducer of in vivo proliferation of growth-arrested A spermatogonia in VAD mouse testis (Gaemers et al., 1996) . CYP26 has originally been cloned from wound epithelium of zebrafish regenerating caudal fin (White et al., 1996) , and mouse (Ray et al., 1997; Abu-Abed et al., 1998) , human (White et al., 1997) , and Xenopus (Hollemann et al., 1998) homologues have also been cloned. CYP26 expression is inducible by RA, involving RARs, and has been studied in a variety of human and mouse cell lines and tissues (Ray et al., 1997; White et al., 1997; Abu-Abed et al., 1998; Marikar et al., 1998; de Roos et al., 1999) .
We wanted to study a possible role for CYP26 in the differentiation of P19 embryonal carcinoma (EC) cells. CYP26 expression is induced by RA within 2 h in P19 EC cells, and coincides with RA metabolism in isolated P19 microsomes. Stable expression of human CYP26 in P19 EC cells resulted in increased RA metabolism to more polar compounds as, e.g., 4-hydroxy-RA and 18-hydroxy-RA, decreased growth inhibition by RA and decreased transactivation of a RAR␤ promoter reporter construct by RA, suggesting an RA inactivation role for CYP26 as proposed earlier (White et al., 1997; Ray et al., 1997) . Strikingly, ectopic expression of CYP26 in P19 cells resulted in neuronal differentiation-in monolayer-in the presence of low levels RA, normally leading to endodermal differentiation, and this neuronal differentiation could be inhibited by the CYP inhibitor liarozole. Finally, the neuronal P19-hCYP26 transfectants evolved into electrically active neurons as measured as excitable cells by patch-clamp analysis. In summary, our results indicate that CYP26 expression is involved in neuronal differentiation of P19 EC cells, possibly via the generation of specific active RA metabolites. The observations suggest an active role for CYP26 in early neuronal development.
MATERIALS AND METHODS
Materials. DF medium (1:1 mixture of Dulbecco's minimal essential medium and Ham's F12, buffered with 44 mM NaHCO 3 ) and fetal calf serum (FCS) were obtained from Life Technologies (Gaithersburg, MD). Liarozole fumarate (R-75251) was a gift from Dr. W. Wouters (Janssen Research Foundation, Beerse, Belgium) and was dissolved at a concentration of 10 mM in ethanol and stored at Ϫ80°C. [11, 12- 3 H]RA (52 Ci/mmol) was obtained from Dupont-New England Nuclear (Boston, MA). RA, 13-cis-RA (both Sigma Chemicals Co., St. Louis, MO), 4-oxo-RA, 4-hydroxy-RA, and 18-hydroxy-RA (all gifts from L. H. Foley, Roche Pharmaceuticals, Nutley, NY) and 9-cis-RA (gift from Dr. J. Bausch, Hoffmann-La Roche, Basel) were dissolved in DMSO at a concentration of 10 mM. Am80 (gift from Dr. K. Shudo, Tokyo, Japan) was dissolved in ethanol at a concentration of 10 mM. Retinoids were stored in the dark at Ϫ80°C. All handling of retinoids was done in a nitrogen atmosphere in a room illuminated with red light only. Further dilutions of all used retinoids were prepared in culture medium.
Cell culture and DNA transfection. P19 cells (clone P19S1801A1; McBurney and Rogers, 1982) were cultured as monolayers on 0.1% (v/v) gelatin-coated tissue culture dishes (Costar Corp., Cambridge, MA) in DF medium containing 7.5% fetal calf serum. To induce differentiation in monolayer, cells were plated at a density of 10.000 cells/cm 2 and incubated with 1 M RA for 4 days. Transfections were performed by the calcium phosphate precipitation procedure. To obtain stable hCYP26 transformants, P19 cells were transfected at 40 -70% confluence in 50-mm dishes with 7.5 g of pSG5-neo-hCYP26 . Transformants were selected with 200 g/ml G418 (Life Technologies, Gaithersburg, MD). After 2 weeks, G418-resistant colonies were isolated, cultured under prolonged G418 selection, and analyzed by Northern analysis for hCYP26 expression.
Transient transfections. P19 and P19-hCYP26 transfectant cells were seeded in 24-well tissue culture plates (30.000 cells/ well). After 24 h, cells were transfected with 2 g reporter plasmid -1470ϩ156hRAR␤2-luc (Folkers and Van der Saag, 1995) and 0.4 g pSV2-lacZ plasmid. After 16 h medium was refreshed and cells were incubated with different concentrations RA or Am80 (1-100 nM) for 24 h. Before harvesting, cells were rinsed twice with PBS and lysed in 250 l Triton-lysis buffer (1% (v/v) Triton X-100, 25 mM glycylglycin (pH 7.8), 15 mM MgSO 4 , 4 mM EGTA, and 1 mM dithiothreitol) for 30 min at 4°C. Cell extracts were analyzed for luciferase activity using the Luclite luciferase gene reporter assay kit (Packard, Canberra, CT) and chemiluminescence was measured in a Topcount scintillation counter (Packard). Values were normalized for transfection efficiency using the ␤-galactosidase assay (Rosenthal, 1987) .
RNA isolation and Northern blot analysis. Total RNA from cell cultures was extracted by the acid guanidinium thiocyanate extraction method (Chomczynski and Sacchi, 1987) . Twenty micrograms of total RNA was fractionated on a 0.8% (w/v) agarose gel containing 2.2 M formaldehyde and blotted onto a Hybond C-extra membrane (Amersham International Ltd., Little Chalfont, Buckinghamshire, UK). The 1.6-kb EcoRI-XhoI fragment from human CYP26 cDNA (White et al., 1997) , a 1.27-kb PCR fragment of mouse CYP26 (see Reverse transcription PCR) (Ray et al., 1997) , and the 1.4-kb PstI fragment from a rat cDNA clone of glyceraldehyde-3-phosphate dehydrogenase were labeled with [ 32 P]dCTP (Amersham) by random priming to a specific activity of more than 10 8 cpm/g DNA. Hybridization was performed in 50% (v/v) formamide/5ϫ standard saline citrate (SSC)/1ϫ Denhardt's solution/0.5% (w/v) sodium dodecyl sulfate (SDS)/10% (w/v) dextran sulfate, and 0.1 mg/ml herring sperm DNA at 42°C for 16 h. The blots were subsequently washed in 2ϫ SSC/0.1% SDS, 1ϫ SSC/0.1% SDS, 0.1ϫ SSC/0.1% SDS for 20 min at room temperature and 0.1ϫ SSC/0.1% SDS for 10 min at 65°C. Autoradiography was for 1-7 days at Ϫ80°C using Kodak X-Omat AR film with an intensifying screen. Signals were quantified by using a Phosphoimager and Image Quant software (Molecular Dynamics, Sunnyvale, CA).
Reverse transcription PCR. P19 cells were treated with 1 M RA for various times and total RNA was isolated. One microgram of total RNA was incubated with 100 ng oligo(dT) 12-18 at 68°C for 5 min and after cooling down to room temperature reversetranscribed using 200 units of Superscript Reverse Transcriptase (Life Technologies, Inc.)/1ϫ Superscript buffer/10 mM dithiotrei-tol, and 500 M of each dNTP at 37°C for 60 min followed by 5 min at 68°C. One-fifth of the first-strand product was added to a PCR amplification mixture, containing 1ϫ Goldstar reaction buffer/1.5 mM MgCl 2 /200 M each of the four dNTPs/0.5 Units of Goldstar Taq polymerase (Eurogentec, Seraing, Belgium)/100 ng of sense primer 5Ј-CTCAAGCTCTGGGACCTGTA-3Ј, and 100 ng of antisense primer 5Ј-AGGAGGTCCATTTAGAAGCTGCCA-3Ј corresponding to basepair positions 91-110 and 1359 -1336 of mouse CYP26 (Ray et al., 1997) , respectively. Mixtures were overlaid with mineral oil and amplification was carried out for 39 cycles in a Perkin-Elmer DNA thermal cycler. Each cycle consisted of 1 min denaturation at 96°C, 1 min annealing at 56°C, and 2 min extension at 72°C. The 1267-bp PCR product was purified using a QIAquick spin-column (Qiagen) and cloned into the pCRII-TOPO vector (InVitrogen, Carlsbad, CA). Semiquantitative RT-PCR was performed as described earlier (Itoh et al., 1997; Boudjelal et al., 1997) , using primers for Nscl2, Ngn1, Stra13, Mash1, Activin, and 36B4 . Each primer set was tested to be in the linear range of product formation. PCR reaction products were separated on 0.8% agarose gels containing Vistra Green (Amersham International Ltd., Little Chalfont, Buckinghamshire, England) and quantified by using a FluorImager and Image Quant software (Molecular Dynamics, Sunnyvale, CA).
Growth inhibition assays. The retinoids' effects on cell proliferation were examined in [ 3 H]thymidine incorporation assays and in soft agar growth assays as described earlier (Todaro et al., 1981; .
Immunofluorescence. Cells were grown on gelatinized (0.1% (v/v)) coverslips and fixed with 2% (w/v) paraformaldehyde in PBS. Subsequently, the cells were washed three times with PBS, permeabilized with 0.1% Triton X-100/PBS, washed three times with PBS, incubated with 0.5% (w/v) BSA/PBS, and washed two times with PBS. Cells were incubated with monoclonal neurofilament 165-kDa (NF-M) antibody (1:1000) in combination with Hoechst (1:500) or monoclonal SSEA-1 antibody (gift from Dr. D. Solter) (1:100) in 10% (v/v) normal goat serum/PBS for 1 h, washed three times with PBS, incubated with a TRITC-conjugated second antibody (1:250) in 10% (v/v) normal goat serum/PBS for 1 h, washed three times with PBS, and mounted in Moviol. The detection of immunostaining was performed by photographing the cells with a Zeiss fluorescence microscope using the TRITC filter set.
TLC and HPLC analysis of retinoid metabolites. Near confluent P19 cultures, grown in 150-mm dishes were treated with 1 M RA for the indicated times. In the case of P19-hCYP26 transfectants no RA was added, but 7.5% (v/v) FCS was present. Microsomal fractions were isolated and assayed for enzymatic conversion of [ 3 H]RA to polar metabolites as described earlier and extracted retinoids were dissolved in 45 l methanol for TLC analysis or in 125 l methanol:60 mM ammonium acetate (9:1, v/v), pH 5.75 for analysis by HPLC. For analysis by HPLC, retinoids were extracted and fractionated from near confluent cell cultures as previously described (Van der Leede et al., 1997) . Retinoid extracts were injected into a reverse-phase HPLC system containing a Spherisorb S50DS2 column (25 ϫ 0.46 cm; Phase Separations, Inc., Franklin, MA) and separated using gradient elution with solvent A (60 mM ammonium acetate, pH 5.75) and solvent B (methanol). The gradient program with a flow rate of 1 ml/min was 5 min isocratic at 65% B, followed by a convex gradient (number 4; Waters Associates) to 85% B in 15 min, a linear gradient to 99% B in 10 min, and 10 min isocratic at 99% B. Radiolabeled retinoids were detected on-line with a LB506 radiochromatography monitor (Berthold, Bad Wildbad, Germany) equipped with a Z-1000 flow cell and a scintillant flow rate of 2 ml/min. Radioinert retinoids were run as standards and detected by measuring the absorbance at 350 nm in a UV flow spectrometer (Phase Separations). Single retinoid peaks were quantified by integration of the peak areas using chromatography software program Winflow version 1.2.1 (Borwin, Le Fontanil, France).
Electrophysiology. P19 cells were aggregated for 4 days in the presence of 1 M RA and subsequently replated on gelatinized coverslips for 3 days. P19-hCYP26 cells (clone P19-hCYP26-10) were differentiated in the presence of 1 M RA for several days as indicated. Experiments were performed at 33°C, using the wholecell configuration of the patch clamp technique (Peppelenbosch et al., 1995) . Responses were recorded through the Axopatch 200B amplifier (Axon Instruments, Inc., Foster City, CA). Output signals were digitized at 2 kHz using a Pentium II personal computer equipped with a PC1200 AD/DAC data acquisition board (National Instruments, Austin, TX). The composition of the bath medium was 140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM glucose, 10 mM Hepes, adjusted to pH 7.45 with NaOH. The pipette composition was 145 mM KCl, 5 mM NaCl, 1 mM CaCl 2 , 10 mM EGTA, 2 mM MgCl 2 , 10 mM Hepes, adjusted to pH 7.30 with KOH.
RESULTS

CYP26 is rapidly induced in P19 EC cells by RA and coincides with RA metabolism. P19 EC cells are a useful
in vitro tool to study early processes in embryonal development, since this pluripotent stem cells of teratocarcinomas can differentiate toward endoderm, mesoderm, or ectoderm in the presence of RA. In various cell types, including HL-60, MCF-7, and T-47D cells, RA metabolism can be induced by RA pretreatment (Takatsuka et al., 1996; Van der Leede et al., 1997; White et al., 1997; . We and others recently showed that RA metabolism is the result of the induction of a novel RA-inducible CYP enzyme, CYP26, which possesses strong RA 4-hydroxylating activity (White et al., 1996; Marikar et al., 1998; . Here we addressed the question of whether in P19 EC cells CYP26 also can be induced by RA, resulting in the metabolism of RA. We cloned a 1267-bp fragment of mouse CYP26 by means of RT-PCR from P19 EC cells and used this fragment in Northern analysis of RNA isolated from P19 and RAC65 EC cells pretreated with 1 M RA for different periods of time. CYP26 was induced transiently in P19 cells by RA treatment with strong expression between 2 and 24 h of RA treatment, and expression strongly decreased between 24 and 48 h (Fig. 1) . In RA-resistant P19 EC-derived RAC65 cells, expressing a dominant negative RAR␣, resulting in decreased RAR function (Kruyt et al., 1992) , CYP26 was not induced by RA (Fig. 1) , suggesting that activated RARs are involved in CYP26 expression. This was already shown for RAR␥ in F9 EC cells (Abu-Abed et al., 1998) and for all three RARs (␣, ␤, and ␥) in human HCT 116 colon carcinoma cells and human keratinocytes (Marikar et al., 1998) . Autoinduction of RA metabolism was studied by TLC analysis (Fig. 2) P19 EC cell lines stably expressing human CYP26 show increased RA metabolism. To study the function of the CYP26 gene in RA-mediated differentiation of P19 cells, we produced P19 cells, stably transfected with human CYP26 cDNA under control of the SV40 early promoter. Neomycin-resistant clones were screened for CYP26 expression by Northern blot analysis using human CYP26 cDNA as a probe, and three clones expressing the transgene (with high, moderate, and low expression levels) were selected: P19-hCYP26-10, P19-hCYP26-14, and P19-hCYP26-55 (Fig. 3A ). These clones were tested for enzymatic activity of the introduced CYP26 by incubating isolated microsomes with the CYP26 substrate [ 3 H]RA for 45 min and analysis of the retinoid products by HPLC . Parental P19 microsomes isolated from untreated P19 EC cells could not metabolize [ 3 H]RA, while microsomes of all three selected clones (P19-hCYP26-10, P19-hCYP26-14, and P19-hCYP26-55) were clearly capable of converting RA to more polar metabolites including 4-hydroxy-RA (peak 2) as the major compound, but also 18-hydroxy-RA (peak 3), 4-oxo-RA (peak 1), and two unidentified peaks (Figs. 3C-3F ). Besides the microsomal assay, we also tested P19 cells and P19-hCYP26 cells for their ability to metabolize RA. P19 and P19-hCYP26 cells were incubated with 10 nM [ 3 H]RA for various times and the RA content in the cells was measured by HPLC analysis (Fig. 4) . P19 cells were capable of metabolizing RA. Within 6 h, 50% of the RA had been converted, although no polar metabolites like 4-hydroxy-RA and 4-oxo-RA could be detected (data not shown). P19 cells pretreated with 1 M RA for 16 h, containing induced CYP26 activity (Fig. 1) , and stable P19-hCYP26 transfectants showed clear increased RA metabolism compared to the parental P19 EC cells. Within 2 h, 50% of the RA had disappeared, and after 6 h no RA could be detected (Fig. 4) . In conclusion, all three P19-hCYP26 clones expressed functional CYP26 enzyme capable of metabolizing RA into more polar metabolites like 4-hydroxy-RA and 18-hydroxy-RA, as determined by the microsomal assay as well as in intact cells.
P19-hCYP26 stable transfectants are decreased in growth inhibition by RA. Treatment of P19 EC cells with RA results in cell growth inhibition as shown by decreased proliferation and loss of the capacity for anchorageindependent growth (Rayner and Graham, 1982) . To study the result of CYP26 expression in P19 on RA-induced growth inhibition, we compared the growth behavior of the P19-hCYP26 transfectants with the P19 parental cells in the presence and absence of RA by means of [ 3 H]thymidine incorporation in monolayer culture and growth assays in soft agar (Fig. 5) . P19 EC cells were very sensitive to RA and demonstrated a concentration-dependent inhibition: Treatment of P19 cells with 1 nM RA showed only 46% [ 3 H]thymidine incorporation (Fig. 5A ) and 25% colony formation (Fig. 5C) (Fig. 5A ). To determine whether the decreased growth inhibition of the P19-hCYP26 transfectants by RA is indeed caused by CYP26 activity, we also performed growth inhibition assays with the synthetic retinoid Am80, which at low concentrations is selective for RAR␣ (Graupner et al., 1991; Roy et al., 1995) . Previously we showed that the CYP26 enzyme is highly specific for RA and does not recognize Am80 as a substrate , and therefore one would expect no difference in growth inhibition by Am80 between P19 and P19-hCYP26 transfectants. This is the case indeed (Fig. 5) ; both [ 3 H]thymidine incorporation (Fig. 5B ) and in soft agar growth assays (Fig. 5D ) the P19-hCYP26 transfectants showed more or less the same growth inhibition pattern by Am80 as for P19 cells, comparable to the growth inhibition profile of P19 EC cells by RA (Figs. 5A and 5C ). This suggests that it is RA itself and not (one of) its metabolites generated by CYP26 which causes the anti-proliferative effects in P19 EC cells.
Expression of human CYP26 in P19 EC cells results in decreased transactivation of a RAR␤ promoter-luc reporter by RA. In P19 EC cells, RA can transactivate the RAR␤2 gene in a concentration-dependent manner, as determined by transient transfections of P19 cells with RAR␤2 promoter constructs coupled to reporter genes (Kruyt et al., 1992; Folkers and van der Saag, 1995) as well as in stable P19 cells harboring the 1.8-kb mRAR␤2 promoter coupled to lacZ . To study the effect of CYP26 expression on transactivation of the RAR␤ gene by RA in P19 cells, we transiently transfected P19 and P19-hCYP26 transfectants with a Ϫ1470ϩ156RAR␤ promoter construct (Folkers and van der Saag, 1995) coupled to the luciferase gene as a reporter. As shown in Fig. 6 , the reporter construct is induced in P19 cells upon RA treatment in a concentration-dependent fashion, with a 200-fold induction after 24 h by 100 nM RA. The P19-hCYP26 transfectants showed a decreased transactivation of the promoter as compared with P19 cells. Treatment with 10 nM RA for 24 h did not result in RAR␤ promoter transactivation, while P19 cells showed a 50-fold induction at this concentration. Even with 100 nM RA treatment for 24 h, both P19-hCYP26 transfectants showed only a 60-fold induction compared to 200-fold in P19 EC cells. To show that this decreased transactivation of the RAR␤ promoter in the P19-hCYP26 transfectants is due to CYP26 activity, we performed the same transfection assay with Am80 as innot (one of) its metabolites generated by CYP26 which causes the strongest RAR␤ induction in P19 EC cells.
hCYP26 promotes neuronal differentiation of P19 EC cells. Based upon the experiments presented so far, decreased growth inhibition by RA and decreased transactivation of the RAR␤ promoter in the P19-hCYP26 transfectants, we can conclude that biologically active RA is inactivated via a negative feedback function of CYP26, as we and others proposed earlier (White et al., 1997; Marikar et al., 1998; . To study the effect of CYP26 expression in RA-induced P19 EC differentiation, we compared differentiation characteristics of P19 EC cells with P19-hCYP26 cells. P19 EC cells are malignant stem cells of mouse teratocarcinomas that resemble the pluripotent stem cells of the inner cell mass of preimplantation embryos, and therefore are widely used as an in vitro model system to study early differentiation events during mammalian embryonic development (Martin, 1980) . Murine P19 EC cells can be differentiated by RA into derivatives of all three germ layers, i.e., endoderm, mesoderm, and (neuro-)-ectoderm, depending on the concentration of RA used and the culture conditions (Bain et al., 1994) . When P19 cells are aggregated and treated with high concentrations of RA (5 ϫ 10 Ϫ7 M), cells differentiate into neural cells sharing several similarities with neurons of the rostral CNS based on their phenotypes of neurotransmitters and receptors Bain et al., 1994) , while aggregates treated with low levels of RA (10 Ϫ8 M) differentiate into endodermal-like cells . In monolayer culture, P19 EC cells can differentiate only toward endodermal and mesodermal derivatives when treated with RA for 4 days (Mummery et al., 1986) . To examine the differentiation state of untreated and RA treated P19 and P19-hCYP26 cells, immunofluorescence was performed with an antibody against murine embryonic antigen SSEA-1, which is a marker for undifferentiated embryonal stem and carcinoma cells (Ballou et al., 1987) . Untreated P19 cells all stained positive (Fig. 7A) , while P19 cells treated with 1 M RA for 4 days have lost SSEA-1 staining, indicating complete differentiation of the P19 EC cells (Fig. 7B) . However, the P19-hCYP26 transfectants only show 40 -60% EC component (Figs. 7C  and 7E ), while SSEA-1 staining decreased to 20 -40% upon RA treatment (Figs. 7D and 7F ). On this basis, RA treatment apparently did not result in complete differentiation of the P19-hCYP26 clones. When P19-hCYP26-10 and P19-hCYP26-14 transfectants growing in monolayer were treated with 1 M RA, neurite extensions appeared already after 1 day (data not shown). After 3 days of RA treatment, these neurite-like structures were extended dramatically and cells resembled morphologically neuronal cells, but also endoderm-like cells appeared. To examine this neuro- nal differentiation process of the P19-hCYP26 transfectants in more detail, immunofluorescence was performed with an antibody against the 165-kDa NF-M protein, which functions as a marker of neuronal differentiation (McBurney et al., 1988) . Untreated and RA-treated (1 M RA for 3 days) wild-type P19 cells did not stain positively with the neurite-specific anti-NF-M antibody (Figs. 7G and 7H ). However, in untreated P19-hCYP26-10 and P19-hCYP26-14 transfectants, staining of neurites was already observed (Figs. 7J and 7M) , and was strongly increased after 3 days of RA treatment (Figs. 7K and 7N ). To study if the observed neuronal differentiation-in monolayer-was due to CYP26 activity, the CYP inhibitor liarozole fumarate (Wouters et al., 1992) was added during the 3 days of RA treatment. Liarozole was shown to be a potent inhibitor and can completely block CYP26 enzyme activity . Indeed, neuronal differentiation-in monolayerobserved in the P19-hCYP26 transfectants upon RA treatment could be severely inhibited by liarozole (Figs. 7L and  7O ). These findings suggest that CYP26 activity might lead to the formation of RA metabolites with specific functions in directing neuronal differentiation. Altered expression of neuronal markers in P19-hCYP26 transfectants. Stable expression of human CYP26 resulted in neuronal differentiation of P19 EC cells under conditions normally leading to endodermal and mesodermal differentiation of these cells. Even without RA treatment, a part of the P19-hCYP26 transfectant cells was already differentiated and contained neurite-like structures. To determine the neuronal state (early or late) of the human CYP26-expressing P19 cells, expression of several markers of neuronal differentiation was analyzed by semiquantitative RT-PCR. This analysis was performed on RNA isolated from cells cultured in monolayer, untreated or treated with 1 M RA up to 4 days. Nscl-2, a basic helix-loop-helix (bHLH) gene expressed in the developing nervous system (Lipkowitz et al., 1992) was transiently expressed in P19 wild-type cells upon differentiation (Fig. 8) . The highest expression is found after 2 days of RA treatment and is decreased rapidly afterward. In P19-hCYP26 transfectants, however, Nscl-2 is already expressed without added RA, and expression is increased after 1-2 days RA of treatment. Neurogenin-1 (ngn1), a novel atonal-related bHLH protein expressed at early stages of neuronal differentiation and involved in neuronal determination in vertebrates Sommer et al., 1996) , was not expressed in P19 EC cells and expression was transiently induced by RA treatment. However, ngn1 expression could already be detected in untreated P19-hCYP26 transfectants, and expression was further increased by RA treatment in a transient fashion (Fig.  8 ) with highest expression after 2 days incubation with RA. Stra13, a novel RA-inducible bHLH gene expressed during mouse embryogenesis which was shown to promote neuronal differentiation of P19 EC cells (Boudjelal et al., 1997) , was induced upon RA treatment of P19 cells with its highest expression at day 4 (Fig. 8) . In the P19-hCYP26 transfectants, stra13 expression was comparable to that in P19 EC cells. Mammalian achaete-scute homologue 1
FIG. 6.
Transactivation of a RAR␤ promoter-luc reporter in P19 EC cells and stable P19-hCYP26 derivatives. P19, P19-hCYP26-10, and P19-hCYP26-14 cells were transiently transfected with a Ϫ1470ϩ156RAR␤2 promoter-luc construct and luciferase activity was measured after 24 h of treatment with different concentrations of RA or Am80. Each point represents the mean of four independent experiments Ϯ SEM.
(mash1), which is expressed in subsets of neuronal precursor cells in the developing nervous system and required for the differentiation of autonomic and olfactory sensory neurons (Johnson et al., 1990; Guillemot and Joyner, 1993; Sommer et al., 1995) , was not expressed in P19 EC cells and could be induced by RA within 1 day (Fig. 8) . In the P19-hCYP26 transfectants, strong mash1 expression was present in untreated cells, while RA treatment increased the expression in a transient fashion with strongest expression after 1 day, which decreased from day 2 of RA treatment onwards. The neuronal markers used in this study for monolayer experiments were previously shown to be highly expressed in P19 aggregates (Boudjelal et al., 1997) . Expression of activin, a mesodermal marker (Smith et al., 1990) , was detectable at low level in P19 EC cells, and expression increased only after 4 days of RA treatment (Fig. 8) . In the untreated P19-hCYP26 transfectants, activin expression was low and increased upon RA treatment after 1 day (clone 14) toward 3 days (clone 10), showing higher expression levels than P19 wild-type cells. This indicates that (part of) the CYP26-expressing P19 cells might differentiate into mesodermal direction after RA treatment, although the neuronal direction is favored, as indicated by the constitutive and inducible expression of neuronal markers.
Electrical properties and action potentials in hCYP26-expressing P19 EC cells. To study the electrophysiological properties of the neuronal P19-hCYP26 transfectants, we investigated the capacity of those cells to evolve into electrically active neurons. P19-hCYP26 cells, cultured in monolayer, were treated with RA for several days, and cells with neuronal morphology were selected for whole-cell patch clamp recording (Peppelenbosch et al., 1995) . In addition, P19 cells aggregated for 4 days in the presence of 1 M RA and replated for 3 days were used as control for neuronal differentiation. Selected neuron-like cells showed upon depolarization fast inward currents followed by more slow outward currents (Fig. 9) . The development of the percentage of excitable cells during the differentiation with RA, measured as active currents, is shown in Fig. 9A . After 3 days of RA treatment, morphologically identified neuronlike cells, which already displayed neurofilament staining (Fig. 7) and expression of several other neuronal markers (Fig. 8) , hardly showed any electrical excitability (only 1 of 15 tested cells was excitable). However, after 4 days of RA treatment, 72% of the selected cells were electrical excitable, increasing up to 90% after 5 days. Representative examples of patch clamp traces are shown in Fig. 9B (at 2 days RA treatment) and Fig. 9C (at 5 days RA treatment). So, although P19-hCYP26 cells appear to be neuronal-like very early after RA treatment based upon morphology and expression of neuronal markers, electrically active neurons, which can participate in electrical neuronal signaling, arise later, from 3 to 4 days after RA treatment.
DISCUSSION
In this paper we report on the role of the recently identified retinoic acid hydroxylase (CYP26) in differentiation of P19 embryonal carcinoma cells. This enzyme, mainly responsible for the 4-hydroxylation of RA, is rapidly inducible by RA in P19 EC cells (within 6 h), and shows maximal enzymatic activity toward all-trans-RA within 16 h. This fast induction occurs at the level of transcription regulated by ligand-bound RARs (Abu-abed et al., 1998; Marikar et al., 1998; . That RARs are necessary for CYP26 expression is demonstrated by RAC65 EC cells, with disturbed RAR signaling, showing no induction of CYP26 upon RA treatment (this study), while stable introduction of RARs (RAR␣, RAR␤, or RAR␥) in this cell line results in restored CYP26 expression (E. Sonneveld and P. T. van der Saag, unpublished results) as shown previously for HCT 116 cells . CYP26 expression is rapidly decreased between 24 and 48 h RA treatment. However, Fujii et al. (1997) described CYP26 expression in P19 EC cells after 2 days RA treatment with maximal expression after 4 days which disappeared after 8 days. This could indicate that CYP26 is induced biphasicly by RA in P19 EC cells, with a first rapid transient induction between 2 and 48 h and a second late transient induction between 2 and 8 days after RA induction. Whether this second transient induction of CYP26 is a direct effect of RA itself is doubtful, since RA is metabolized completely within 16 h. Therefore, other CYP26 regulatory factors FIG. 8. Stable expression of human CYP26 in P19 cells results in an altered expression of neuronal markers. P19, P19-hCYP26-10, and P19-hCYP26-14 cells were grown in monolayer in the absence or the presence of 1 M RA for 1 to 4 days. Total RNA was isolated and reverse transcribed and transcripts for each gene were analyzed by semiquantitative PCR. The amount of reverse transcribed RNA in each reaction was normalized with transcripts of the 36B4 gene that is unresponsive to RA treatment (Krowczynska et al., 1989) . might exist which probably will be identified after isolation of the CYP26 promoter sequence.
Stable expression of human CYP26 under a constitutive promoter (SV40) in P19 EC cells results in highly increased RA metabolism with 4-hydroxy-RA and 18-hydroxy-RA as predominant metabolites, indicating that the enzyme is present and active in these transfectants. In these transfectants, RA is cleared from the cells and the medium within 6 h, which normally occurs within 16 h in P19 EC cells. The metabolic profile of the P19-hCYP26 transfectants is identical to the profile recently described for RA-treated T-47D human breast cancer cells and CYP26-overexpressing HCT 116 colon carcinoma cells (Van der Leede et al., 1997; .
CYP26 is rapidly induced by RA itself in a variety of cell lines, including EC cells. Induction of CYP26, and as a consequence RA metabolism, is only possible in cell lines known to be sensitive for RA, e.g., with respect to growth inhibition. CYP26-overexpressing P19 EC cells show markedly decreased growth inhibition by RA compared to parental P19 EC cells, as demonstrated by thymidine incorporation and colony growth in soft agar. This suggests that CYP26 activity is not involved in formation of metabolites that mediate growth inhibition as proposed earlier by Takatsuka et al. (1996) , but rather leads to the formation of inactive retinoids. This idea is strengthened by the observation that overexpression of CYP26 in RA-resistant cell lines (MDA-MB-231 breast tumor cells and HCT 116 colon carcinoma cells) does not result in restored growth inhibition by RA (E. Sonneveld and P. T. van der Saag, unpublished results) . This indicates a negative feedback function for CYP26, probably to protect the cell from an overdosage of RA, as proposed previously for CYP24-involved vitamin D 3 catabolism (Makin et al., 1989) . However, new insight in the function(s) of the formed metabolite 24,25-dihydroxyvitamin D has been gathered, and specific active roles for this metabolite have been proposed (reviewed by St. Arnaud and Glorieux, 1998) .
Stable expression of CYP26 in P19 EC cells results in neuronal differentiation of these cells accompanied by early expression of several neuronal markers, under conditions normally leading to endodermal and mesodermal differentiation only. Low levels of retinoids (between 10 and 100 nM retinol and 0.1 and 1 nM RA; data not shown) present in the medium (provided by the serum present) seem to be sufficient to induce neuronal differentiation of CYP26-expressing P19 cells since these transfectants already show neurites in the absence of added RA, while number and length of the extensions increased dramatically upon RA treatment. At this point there seems to be contradictory data. P19 EC cells growing in monolayer will never differentiate into neuronal-like cells, even though CYP26 expression is induced very fast after RA treatment (within 2 h) and enzymatic activity is present within 6 h. One could argue that if CYP26 is essential for neuronal differentiation, P19 cells would undergo neuronal differentiation in monolayer after RA treatment and the consequent expression of CYP26. One possibility is the greater amount of metabolites in the CYP26 transfectants, leading to neuronal differentiation. Second, the RA-induced expression of CYP26 might occur too late, e.g., P19 cells may already be committed to endodermal differentiation by the action of RA itself (by the super fast induction of endoderm specific genes) and not its metabolites. In the CYP26-expressing P19 cells, RA treatment directly results in the formation of hydroxylated metabolites which on their turn might induce the onset of early neuronal differentiation, via transcription of neuronal specific genes (mash1, ngn1, nscl2, etc.), a situation which normally might only occur in P19 aggregates, via mechanisms not known yet. Alternatively, the rapid clearance of RA in the P19-hCYP26 transfectants upon RA treatment may result in repression of genes required for endodermal differentiation, creating a cellular environment for the activation of neuronal genes as a default mechanism (Hemmati-Brivanlou and Melton, 1997). RAR␤ seems not to play a role in the onset of neuronal differentiation because in hCYP26-expressing P19 cells a RAR␤ promoter-luciferase reporter construct is hardly induced by RA, whereas in parental P19 cells induction of this construct is extensive upon RA treatment. The fact that we obtained multiple hCYP26-expressing P19 EC clones which show neuronal morphology after RA treatment rules out the possibility that we are dealing with a clonal artefact. This is furthermore strengthened by the observation that embryonic stem (ES) cells stably transfected with hCYP26 also display a neuronal phenotype (E. Sonneveld et al., manuscript in preparation) .
bHLH proteins comprise an expanding gene family of transcription factors of which several members have been identified as important regulators of neurogenesis (for reviews see Crews, 1998; Dambly-Chaudiè re and Vervoort, 1998; Sasai, 1998) . Evidence is accumulating that earlyacting bHLH genes such as ngn1, ngn2, and stra13, control the determination of different proneural cell lineages Sommer et al., 1996; Boudjelal et al., 1997; Fode et al., 1998; Ma et al., 1998) , preceding the expression of bHLH genes controlling neuronal differentiation, such as mash1, nscl2, and neuroD (Lipkowitz et al., 1992; Guillemot and Joyner, 1993; Lee et al., 1995; Sommer et al., 1995; Itoh et al., 1997) , and both types of neural bHLH genes often act in cascades (Ma et al., 1998) . Untreated hCYP26-expressing P19 EC cells express "early" determination bHLH genes, as well as "late" differentiation bHLH genes, while expression of both types is further increased by RA. This expression of multiple position-specific neuronal markers suggests the presence of various CNS neuronal cell types in the P19-hCYP26 transfectants or possibly combined in one cell.
The neuronal nature of the hCYP26 expression P19 EC cells was furthermore confirmed by measuring the electrophysiological properties of these neuronal cells. Within the first 3 days of RA treatment, P19-hCYP26 transfectants showed no electrical excitability, as measured by patchclamp currents, but after 5 days almost all selected cells were excitable. This development of the percentage of excitable cells during the differentiation of these transfectants by RA treatment is in agreement with electrophysiological properties observed for neuronal P19 and ES aggregates Okabe et al., 1996) and P19 and ES cells stably transfected with RPTP␣, respectively (Den Hertog et al., 1993; Van Inzen et al., 1996) . So, although P19-hCYP26 cells appear to be neuronal-like very early after RA treatment based upon morphology and expression of neuronal markers, functionally active neurons arise later.
That RA is generally involved in the development of the CNS has been known for some time now, based upon RA depletion, RA overdosage, and RA receptor knock-out studies (Durston et al., 1989; Kastner et al., 1995; Båvik et al., 1996; Maden et al., 1996; Dickman et al., 1997; White et al., 1998) . Recent papers now show a specific role for the retinoid pathway in specifying positional identity and determination of cells in the CNS (Gould et al., 1998; Sockanathan and Jessell, 1998; Solomin et al., 1998; Maden et al., 1998; reviewed by Maden, 1998) . However, it is not known if this specific role is due to the direct action of RA itself or whether it could be caused by specific metabolites of RA. Based upon in vitro data presented in this paper we suggest the latter possibility with CYP26 catalyzing the formation of these metabolites. Isolation and characterization of these metabolites proves this hypothesis. In addition, CYP26 is highly expressed in the developing CNS, such as hindbrain ectoderm, cephalic mesenchyme (including migrating neural crest cells), and caudal neural plate (Fujii et al., 1997; Trofimova-Griffin and Juchau, 1998; de Roos et al., 1999; Iulianella et al., 1999) .
In summary, this paper describes the first report on the involvement of RA metabolism in neurogenesis as studied by the P19 EC cell system, a well-established in vitro system for studying neuronal differentiation. Furthermore, the generation of hCYP26-expressing P19 EC cells provides a new, useful, and simplified tool for studying early neuronal differentiation in vitro and measurements of fully mature neurons, bypassing laborious cell aggregation procedures of these cells.
